US3712899A - P-aminoalkylbenzenesulfonamide derivatives - Google Patents

P-aminoalkylbenzenesulfonamide derivatives Download PDF

Info

Publication number
US3712899A
US3712899A US00068794A US3712899DA US3712899A US 3712899 A US3712899 A US 3712899A US 00068794 A US00068794 A US 00068794A US 3712899D A US3712899D A US 3712899DA US 3712899 A US3712899 A US 3712899A
Authority
US
United States
Prior art keywords
imino
imidazolidine
ethyl
phenylsulphonyl
phenylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00068794A
Inventor
H Dietrich
C Lehmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Novartis Corp
Original Assignee
Ciba Geigy Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Corp filed Critical Ciba Geigy Corp
Application granted granted Critical
Publication of US3712899A publication Critical patent/US3712899A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/46—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms attached to said nitrogen atoms

Definitions

  • the present invention relates to derivatives of l-[pcarboxamidoalkyl) phenylsulfonyl] 2 iminoimidazolidines, to pharmaceutical compositions containing these compounds and to the use thereof.
  • the present invention relates to compounds of formula H (1) wherein R is alkyl having at most six carbon atoms, cycloalkyl having from five to eight carbon atoms, phenylalkyl having at most nine carbon atoms or allyl;
  • R is hydrogen, methyl or ethyl
  • R is a five to six membered mononuclear heterocycle with one or two heteroatoms, which is unsubstituted or substituted by lower alkyl or phenyl, and of which a methylene group can be replaced by a carbonyl group;
  • n is the integer 2 or 3;
  • cycloalkyl group can be the cyclopentyl group, which can be optionally substituted by alkyl groups having 13 carbon atoms, the cyclohexyl group, which can be substituted by ethyl or methyl, and the cycloheptyl group optionally substituted by methyl, as Well as the cyclooctyl group; as the phenylalkyl group, R
  • 3,712,899 Patented Jan. 23, 1973 can be the benzyl, the phenethyl or the a-methylphenethyl group.
  • the substituent R embraces mononuclear heterocycles having 5-6 ring members, including 1-2 heteroatoms, whereby suitable hetero atoms are nitrogen, oxygen and sulfur. Accordingly, as a heterocycle having 5 ring members, R, can be, e.g. furan, tetrahydrofuran, thiophene, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, thiazolidine and pyrrolidinone.
  • R can be, e.g. pyridine, pyrimidine, pyrazine or pyridazine.
  • heterocycles can be substituted by lower alkyl groups and/or by phenyl groups. Further, a methylene group being present in one of these rings can be substituted by a carbonyl group.
  • compounds of Formula I are produced by reacting a compound of formula wherein R R and m have the meaning given under Formula I, with a carboxylic acid of formula Rg-COOH (III) or with a reactive derivative of such a carboxylic acid, wherein R, has the meaning given under Formula I; and, optionally, converting the obtained reaction products into the salt of an inorganic or organic acid.
  • the reaction of a carboxylic acid of Formula HI with an amine of Formula II can be performed by firstly producing the corresponding carboxylic acid salt of the amine, and converting this, by subsequent heating, into the amide of Formula I.
  • an amine of Formula II is reacted with a carboxylic acid of Formula III in an inert solvent at temperatures of -5 to +5 C. in the presence of a water-splitting agent.
  • inert solvents it is possible to use, e.g.
  • hydrocarbons such as a benzene, toluene or xylene, ethers such as diethyl ether, dioxane or tetrahydrofuran, chlorinated hydrocarbons such as methylene chloride, and lower ketones suchas acetone or methyl ethyl ketone.
  • a suitable water-splitting agent is, in particular, N,N-dicyc1ohexylcarbodiimide.
  • carbonyldipyrazole it is also possible to use carbonyldipyrazole.
  • Suitable reactive derivatives of a carboxylic acid of Formula III are, e.g. halides, lower alkyl esters, especially methyl or ethyl ester, phenyl ester, amides, lower monoor dialkylamides, particularly N-methyl amides and N,N- dimethylamides, diphenylamides, also N-acylamides such as, e.g. acetylamides and benzoylamides.
  • reaction of reactive derivatives of a carboxylic acid of Formula III with amines of Formula II is performed, e.g. at room temperature, or by heating in an inert organic solvent. Suitable as such are, e.g. the above already mentioned solvents.
  • the reaction can be carried out without the addition of condensation agents; such agents, e.g. alkali metal alcoholates and alkali metal hydroxides, may, however, optionally be added.
  • a halide of a carboxylic acid of Formula IH is reacted according to the invention preferably in the presence of an acid-binding agent.
  • inorganic bases or salts can be used such as, e.g. an alkali hydroxide, -acetate, -hydrogen carbonate, -carbonate and -phosphate, such as sodium hydroxide, -acetate, -hydrogen carbonate, -carbonate and -phosphate, or the corresponding potassium compounds. It is also possible to use calcium oxide, -carbonate, as well as -phosphate, and magnesium carbonate. Also suitable, in place of inorganic bases or salts, are organic bases such as, e.g. pyridine, trimethylamine or triethylamine, diisopropylamine, or collidine. Added in excess, these may also be used as solvent.
  • organic bases such as, e.g. pyridine, trimethylamine or triethylamine, diisopropylamine, or collidine. Added in excess, these may also be used as solvent.
  • N-alkali metal derivatives of these compounds such as, e.g. sodium, potassium or lithium derivatives.
  • the starting compounds of Formula II are, for their part, new compounds and may be produced, e.g. by reacting a reactive derivative of a sulphonic acid of for- H (IV) wherein R represents an alkyl or aryl radical, e.g. a methyl or a phenyl group, and
  • n has the meaning given in Formula I, with a 2-amino-2- imidazoline derivatives of formula ILIHQ wherein R and R have the meaning given under Formula I,
  • Suitable reactive derivatives of a sulphonic acid of Formula IV are halides, especially chlorides and anhydrides of Formula wherein R and m have the meaning given under Formulas IV and I.
  • the anhydrides of Formula IVa can be obtained in a simple manner by the reaction of corresponding substituted sulphonic acid halides with salts of correspondingly substituted sulphonic acids.
  • starting materials of Formula II are obtained by reacting substituted p-(aminoalkyl)- benzenesulphonamides, (produced analogously to the method of E. Miller, J. Amer. Chem. Soc. 62, 2101 (1940)) of formula wherein in has the meaning given under Formula I, with substituted N-(Z-bromoalkyl)-cyanamides in alkaline medium.
  • the preparation of the starting compounds of Formula HI is carried out using the generally known preparation methods for the corresponding carboxylic acid derivatives.
  • the new active substances of Formula I, or the pharmaceutically acceptable salts thereof, can be administered orally, rectally or parenterally.
  • physiologically harmless inorganic or organic acids such as, e.g. hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, acetic acid, lactic acid, succinic acid, tartaric acid and maleic acid; but also hypoglycemic sulfonyl ureas such as, e.g.
  • the compounds of the invention are administered in amounts depending on the species, the
  • the daily dosage varies between about 0.1 and 100 mg./kg. of body weight for warm blooded animals.
  • Suitable dosage units such as drages or tablets preferably contain 10-200 mg. of an active substance according to the invention, whereby the content of active substance is 20- by weight.
  • the tablets and drages are produced by combining the active substance, e.g.
  • solid pulverulent carriers such as lactose, saccharose, sorbitol or mannitol; starches such as potato starch, maize starch or amylopectin, also laminaria powder or citrus pulp powder, cellulose derivatives or gelatine, optionally with the addition of lubricants such as magnesium or calcium stearate, or polyethylene glycols of suitable molecular weights.
  • the tablets and drage cores are coated, e.g. with concentrated sugar solutions which can also contain, e.g. gum arabic, talcum and/or titanium dioxide, or with a lacquer dissolved in readily volatile organic solvents or mixtures of solvents.
  • Dyestuffs may be added to these coatings, e.g. for identification of the various dosage amounts.
  • suitable dosage units for oral administration are hard gelatine capsules, as well as soft closed capsules made from gelatine and a softener such as glycerin.
  • the hard capsules contain the active substance preferably as a granulate, e.g. in admixture with fillers such as maize starch, and/or lubricants such as talcum or magnesium stearate, and optionally stabilisers such as sodium metabisulphite (Na S O or ascorbic acid.
  • the active substance is preferably dissolved or suspended in suitable liquids such as liquid polyethylene glycols, whereby likewise stabilisers may be added.
  • a granulate is produced from 1000 g. of 1-[p-(2- nicotinamidoethyl) phenylsulphonyl] 2-imino-3-cyclohexylimidazolidine, 345.0 g. of lactose and the aqueous solution of 6.0 g. of gelatine. After drying, the granulate is mixed with 10.0 g. of colloidal silicon dioxide, 40.0 g. of talcum, 40.0 g. of potato starch and 5.0 g. of magnesium stearate; the mixture is then pressed into 10,000 drage cores.
  • Example 1 An amount of 39.7 g. of 1-[p-(Z-aminoethyl)-phenylsulfonyl]-2-imino-3-tert.-butyl-imidazo1idine dihydrochloride monohydrate, M.P. 232234, is dissolved in 200 ml. of water; and the base liberated with ml. of 2-n sodium hydroxide solution. It is extracted with methylene chloride. To the methylene chloride solution, dried with sodium sulfate, are added 15 g. of triethylamine. To this solution are thereupon added dropwise at room temperature, within 20 minutes, 15 g. of furan-Z-carboxylic acid chloride in 100 ml.
  • the dihydrochlorides (used as starting materials) of 1 [p (2 aminoethyl) phenylsulphonyl]-2-iminoimidazolidines varying substituted in the 3-position can be obtained, e.g. in a simple manner by reaction of p-(2- acylamidoethyl)-benzenesulphochloride with correspondingly substituted 2amino-imidazolines of Formula V, and subsequent hydrolytic cleavage of the acyl radical of the p-acylamindoethyl group with aqueous hydrochloric acid, as is described in the following for 1-[p-(2-aminoethyl)- phenylsulphonyl] 2 imino-3-cyclohexyl-imidazolidine dihydrochloride.
  • the applied sulphochlor-ide can be produced as follows: To 35.0 g. of chlorosulphonic acid are added portionwise, with stirring, 16.3 g. of N-phenethylacetamide. The obtained mixture is stirred for 3 hours at 60, and then poured on to ice, whereby p-(Z-acetamidoethyl)-benzenesulphochloride precipitates in crystalline form. It is filtered 01f under suction, washed with water, dried in vacuco, and further processed as crude product.
  • Example 2 42.3 g. of 1-[p-(2-aminoethyl)-phenylsulfonyl]-2- irnino-3-cyclohexyl-imidazolidine dihydrochloride, M.P. 247-25 0 are dissolved in 200 ml, of Zn sodium hydroxide the free base is extracted with methylene chloride, the extract is dried over sodium sulfate and the methylene chloride is distilled off in vacuo. The residue is then taken up with 300 ml. of dioxane and after addition of 16.0 g. of nicotinic acid methyl ester and 0.5 g. of sodium methylate the whole is refluxed for 4 hours. The solvent is distilled oil?
  • Example 3 42.3 g. of 1-[p-(Z-aminoethyl)-phenylsulphonyl]-2- imino-3-cyclohexyl-imidazolidine dihydrochloride, M.P. 247-25 0 are dissolved in 200 ml. of water. After addition of ml. of 2-n sodium hydroxide the free base is taken up with methylenechloride and the methylenechloride solution is dried over sodium sulphate. Then 12.3 g. of nicotinic acid and 60 g. of N,N'-dicyclohexy1 carbodiimide are added. The whole is kept for 1 hour at room temperature and evaporated to dryness in vacuo.
  • Example 4 Analogously to Example 1 are obtained:
  • nicotinic acid chloride 1-[p-(Z-nicotinamido-ethyl)- phenylsulphonyH-Z-imino 3 benzyl-imidazolidine, M.P. 173-175 From 44.5 g. l-[p-(Z-amino-ethyl)-phenylsulphonyl]- 2-imino 3 (2-phenethyl)-imidazolidine-dihydrochloride and 15.0 g.
  • furan-2-carboxylic acid chloride 1[p-(2-(2- furancarboxamido)-ethyl)-phenylsulphonyl] 2 imino 3-(Z-phenethyl)-imidazolidine, M.P. 182-183";
  • furan-Z-carboxylic acid chloride I-[p-(Z-(Z-furancarboxamido)-ethyl)-phenylsulphonyl] 2 imino 3 methylimidazolidine, M.P. 210.5-211.5;
  • R is alkyl of at most six carbon atoms, cycloalkyl or alkyl substituted cycloalkyl of, in all, from five to eight carbon atoms, phenylalkyl of at most three carbon atoms in the alkyl chain, or allyl;
  • R is hydrogen, methyl or ethyl
  • R is a five to six membered mononuclear heterocycle with one or two heteroatoms, which is unsubstituted or substituted by lower alkyl or phenyl and of which a methylene group can be replaced by a carbonyl group furan, thiophene or pyridine, which is unsubstituted or substituted by lower alkyl;
  • n is the integer 2 or 3;
  • a compound according to claim 1 which is 1-[p-(2- (3-furancarboxamido)-ethyl)-phenylsulfonyl] 2 imino- 3-cyclohexyl-imidazolidine.
  • a compound according to claim 1 which is 1-[p-(2- (2 thiophenecarboxamido) ethyl) phenylsulfony1]-2- imino-3-cyclopentyl-imidazolidine.
  • a compound according to claim 1 which is 1-[p-(2- (2 thiophenecarboxamido) ethyl) phenylsulfonyl]- 2-imino-3-cyclohexyl-imidazolidine.
  • a compound according to claim 1 which is 1-[p-(2- nicotinamidoethyl)-phenylsulfonyl] 2 imino 3 cyclohexyl-imidazolidine.
  • R is furan, which is unsubstituted or substituted by lower alkyl.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

COMPOUNDS OF THE CLASS OF 1 - (P-(CARBOXAMIDOALKYL)PHENYLSULFONYL) - 2 - IMINO-IMIDAZOLIDINES AND THE PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF HAVE HYPOGLYCEMIC ACTIVITY; THESE COMPOUNDS ARE ACTIVE INGREDIENTS OF PHARMACEUTICAL COMPOSITIONS AND ARE USEFUL FOR THE TREATMENT OF DIABETES MELLITUS; A TYPICAL EMBODIMENT IS 1 - (P-(2-(3-FURANCARBOXAMIDO)-ETHYL)-PHENYLSULSULFONYL)-2-IMINO-3-CYCLOHEXYL -IMIDAZOLIDINE.

Description

United States Patent ice 3,712,899 p-AMINOALKYLBENZENESULFONAMIDE DERIVATIVES Henri Dietrich, Arlesheim, Basel-Land, and Claude Lehmann, Basel, Switzerland, assiguors to Ciba-Geigy Corporation, Basel, Switzerland No Drawing. Filed Sept. 1, 1970, Ser. No. 68,794 Claims priority, application Switzerland, Sept. 4, 1969, 13,399/69 Int. Cl. C07d 49/30, 57/00 US. Cl. 260-2943 F 6 Claims ABSTRACT OF THE DISCLOSURE Compounds of the class of l [p-(carboxamidoalkyl)- phenylsulfonyl] 2 imino-imidazolidines and the pharmaceutically acceptable acid addition salts thereof have hypoglycemic activity; these compounds are active ingredients of pharmaceutical compositions and are useful for the treatment of diabetes mellitus; a typical embodiment is 1 [p-(2-(3-furancarboxamido)-ethyl)-phenylsulsulfonyl] -2-imino-3-cyclohexyl-imidazolidine.
DETAILED DESCRIPTION The present invention relates to derivatives of l-[pcarboxamidoalkyl) phenylsulfonyl] 2 iminoimidazolidines, to pharmaceutical compositions containing these compounds and to the use thereof.
More particularly, the present invention relates to compounds of formula H (1) wherein R is alkyl having at most six carbon atoms, cycloalkyl having from five to eight carbon atoms, phenylalkyl having at most nine carbon atoms or allyl;
R is hydrogen, methyl or ethyl;
R is a five to six membered mononuclear heterocycle with one or two heteroatoms, which is unsubstituted or substituted by lower alkyl or phenyl, and of which a methylene group can be replaced by a carbonyl group;
and
m is the integer 2 or 3;
tert.butyl, isobutyl, pentyl, isopentyl, 2,2-dimethylpropyl,
l methylbutyl, 1-ethylpropyl, 1,2-dimethylpropy1 or a hexyl group, e.g. an n-hexyl, methylpentyl, dimethylbutyl or ethylbutyl group; as the cycloalkyl group, R, can be the cyclopentyl group, which can be optionally substituted by alkyl groups having 13 carbon atoms, the cyclohexyl group, which can be substituted by ethyl or methyl, and the cycloheptyl group optionally substituted by methyl, as Well as the cyclooctyl group; as the phenylalkyl group, R
3,712,899 Patented Jan. 23, 1973 can be the benzyl, the phenethyl or the a-methylphenethyl group.
The substituent R embraces mononuclear heterocycles having 5-6 ring members, including 1-2 heteroatoms, whereby suitable hetero atoms are nitrogen, oxygen and sulfur. Accordingly, as a heterocycle having 5 ring members, R, can be, e.g. furan, tetrahydrofuran, thiophene, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, thiazolidine and pyrrolidinone.
As a heterocyclic radical having 6 ring members, R can be, e.g. pyridine, pyrimidine, pyrazine or pyridazine.
The above mentioned heterocycles can be substituted by lower alkyl groups and/or by phenyl groups. Further, a methylene group being present in one of these rings can be substituted by a carbonyl group.
Using the process according to the invention, compounds of Formula I are produced by reacting a compound of formula wherein R R and m have the meaning given under Formula I, with a carboxylic acid of formula Rg-COOH (III) or with a reactive derivative of such a carboxylic acid, wherein R, has the meaning given under Formula I; and, optionally, converting the obtained reaction products into the salt of an inorganic or organic acid.
The reaction of a carboxylic acid of Formula HI with an amine of Formula II, can be performed by firstly producing the corresponding carboxylic acid salt of the amine, and converting this, by subsequent heating, into the amide of Formula I. Preferably, an amine of Formula II is reacted with a carboxylic acid of Formula III in an inert solvent at temperatures of -5 to +5 C. in the presence of a water-splitting agent. As inert solvents, it is possible to use, e.g. hydrocarbons such as a benzene, toluene or xylene, ethers such as diethyl ether, dioxane or tetrahydrofuran, chlorinated hydrocarbons such as methylene chloride, and lower ketones suchas acetone or methyl ethyl ketone. A suitable water-splitting agent is, in particular, N,N-dicyc1ohexylcarbodiimide. Furthermore, it is also possible to use carbonyldipyrazole.
Suitable reactive derivatives of a carboxylic acid of Formula III are, e.g. halides, lower alkyl esters, especially methyl or ethyl ester, phenyl ester, amides, lower monoor dialkylamides, particularly N-methyl amides and N,N- dimethylamides, diphenylamides, also N-acylamides such as, e.g. acetylamides and benzoylamides.
The reaction of reactive derivatives of a carboxylic acid of Formula III with amines of Formula II is performed, e.g. at room temperature, or by heating in an inert organic solvent. Suitable as such are, e.g. the above already mentioned solvents. In general, the reaction can be carried out without the addition of condensation agents; such agents, e.g. alkali metal alcoholates and alkali metal hydroxides, may, however, optionally be added.
A halide of a carboxylic acid of Formula IH is reacted according to the invention preferably in the presence of an acid-binding agent.
As acid-binding agents, inorganic bases or salts can be used such as, e.g. an alkali hydroxide, -acetate, -hydrogen carbonate, -carbonate and -phosphate, such as sodium hydroxide, -acetate, -hydrogen carbonate, -carbonate and -phosphate, or the corresponding potassium compounds. It is also possible to use calcium oxide, -carbonate, as well as -phosphate, and magnesium carbonate. Also suitable, in place of inorganic bases or salts, are organic bases such as, e.g. pyridine, trimethylamine or triethylamine, diisopropylamine, or collidine. Added in excess, these may also be used as solvent.
Instead of amines of Formula II, it is also possible to use, for the reaction (according to the invention) with a carboxylic acid chloride, N-alkali metal derivatives of these compounds such as, e.g. sodium, potassium or lithium derivatives.
The starting compounds of Formula II are, for their part, new compounds and may be produced, e.g. by reacting a reactive derivative of a sulphonic acid of for- H (IV) wherein R represents an alkyl or aryl radical, e.g. a methyl or a phenyl group, and
m has the meaning given in Formula I, with a 2-amino-2- imidazoline derivatives of formula ILIHQ wherein R and R have the meaning given under Formula I,
and subsequently hydrolytically splitting olf the protective acyl group (RCO--). The N-acyl com pounds derived from Formula II, obtained as intermediates, have likewise not been hitherto described in the literature.
Suitable reactive derivatives of a sulphonic acid of Formula IV are halides, especially chlorides and anhydrides of Formula wherein R and m have the meaning given under Formulas IV and I. The anhydrides of Formula IVa can be obtained in a simple manner by the reaction of corresponding substituted sulphonic acid halides with salts of correspondingly substituted sulphonic acids.
Using a further process, starting materials of Formula II are obtained by reacting substituted p-(aminoalkyl)- benzenesulphonamides, (produced analogously to the method of E. Miller, J. Amer. Chem. Soc. 62, 2101 (1940)) of formula wherein in has the meaning given under Formula I, with substituted N-(Z-bromoalkyl)-cyanamides in alkaline medium.
The preparation of the starting compounds of Formula HI is carried out using the generally known preparation methods for the corresponding carboxylic acid derivatives.
The new active substances of Formula I, or the pharmaceutically acceptable salts thereof, can be administered orally, rectally or parenterally. For salt formation, it is possible to use physiologically harmless inorganic or organic acids such as, e.g. hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, acetic acid, lactic acid, succinic acid, tartaric acid and maleic acid; but also hypoglycemic sulfonyl ureas such as, e.g. p-toluenesulphonylbutyl urea, p-chlorobenzenesulphonylpropyl urea and p-[2-'(Z-methoxy-S-chlorobenzamido -ethyl -phenylsulfonyl-cyclohexyl urea.
For their intended use, the compounds of the invention are administered in amounts depending on the species, the
age, weight and the particular condition of the individuals being treated, and the mode of administration. In general, the daily dosage varies between about 0.1 and 100 mg./kg. of body weight for warm blooded animals. Suitable dosage units such as drages or tablets preferably contain 10-200 mg. of an active substance according to the invention, whereby the content of active substance is 20- by weight. The tablets and drages are produced by combining the active substance, e.g. with solid pulverulent carriers such as lactose, saccharose, sorbitol or mannitol; starches such as potato starch, maize starch or amylopectin, also laminaria powder or citrus pulp powder, cellulose derivatives or gelatine, optionally with the addition of lubricants such as magnesium or calcium stearate, or polyethylene glycols of suitable molecular weights. The tablets and drage cores are coated, e.g. with concentrated sugar solutions which can also contain, e.g. gum arabic, talcum and/or titanium dioxide, or with a lacquer dissolved in readily volatile organic solvents or mixtures of solvents. Dyestuffs may be added to these coatings, e.g. for identification of the various dosage amounts.
Other suitable dosage units for oral administration are hard gelatine capsules, as well as soft closed capsules made from gelatine and a softener such as glycerin. The hard capsules contain the active substance preferably as a granulate, e.g. in admixture with fillers such as maize starch, and/or lubricants such as talcum or magnesium stearate, and optionally stabilisers such as sodium metabisulphite (Na S O or ascorbic acid. In soft capsules, the active substance is preferably dissolved or suspended in suitable liquids such as liquid polyethylene glycols, whereby likewise stabilisers may be added.
The following prescriptions serve to further illustrate the production of tablets and drages:
(a) 1000 g. of 1-[p-(2-(2-furancarboxamido)-ethyl)- phenylsulphonyl]-2-imino-3-cyclohexy1-irnidazolidine are mixed with 500 g. of lactose and 270 g. of potato starch; the mixture is then moistened with an aqueous solution of 8.0 g. of gelatine, and granulated through a sieve. After drying of the granulate, 60.0 g. of potato starch, 60.0 g. of talcum, 10.0 g. of magnesium stearate and 20.0 g. of colloidal silicon dioxide are mixed in; the mixture is then pressed to form 10,000 tablets each weighing 200 mg. and each containing mg. of active substance. Optionally, the tablets may be provided with grooves to facilitate a more precise adjustment of the dosage amount.
(b) A granulate is produced from 1000 g. of 1-[p-(2- nicotinamidoethyl) phenylsulphonyl] 2-imino-3-cyclohexylimidazolidine, 345.0 g. of lactose and the aqueous solution of 6.0 g. of gelatine. After drying, the granulate is mixed with 10.0 g. of colloidal silicon dioxide, 40.0 g. of talcum, 40.0 g. of potato starch and 5.0 g. of magnesium stearate; the mixture is then pressed into 10,000 drage cores.
These are subsequently coated with a concentrated syrup made from 533.0 g. of crystallised saccharose, 20.0 g. of shellac, 75.0 g. of gum arabic, 250 g. of talcum, 20 g. of colloidal silicon dioxide and 1.5 g. of dyestuff; and then dried. The obtained drages each weigh 240 mg. and each contain 100 mg. of active substance.
The following examples further illustrate the preparation of the new compounds of Formula I and of intermediate products not described hitherto; but these examples in no way constitute the only embodiments thereof. The temperatures are given in degrees centigrade.
Example 1 An amount of 39.7 g. of 1-[p-(Z-aminoethyl)-phenylsulfonyl]-2-imino-3-tert.-butyl-imidazo1idine dihydrochloride monohydrate, M.P. 232234, is dissolved in 200 ml. of water; and the base liberated with ml. of 2-n sodium hydroxide solution. It is extracted with methylene chloride. To the methylene chloride solution, dried with sodium sulfate, are added 15 g. of triethylamine. To this solution are thereupon added dropwise at room temperature, within 20 minutes, 15 g. of furan-Z-carboxylic acid chloride in 100 ml. of methylene chloride. After the solution has been stirred for 1 hour at room temperature, it is washed with 100 ml. of water, then with 1 ml. of 2-n sodium hydroxide solution, and afterwards a further twice with 100 ml. of water. The methylene chloride phase yields after drying with sodium sulfate filtration, and concentration by evaporation, 1-[p-(Z-(Z-furancarboxamido)-ethyl) phenylsulfonyl] 2-imino-3-tert.-butyl-imidazolidine which, recrystallised from ethyl acetate, melts at 143- 144.
The following are obtained analogously to Example 1:
(a) From 42.3 g. of I-[p-(Z-aminoethyl)-phenylsulfonyl] 2-imino-3-cyclohexyl-imidazolidine dihydrochloride, M.P. 247-250, and 15.0 g. of furan-2-carboxylic acid chloride is obtained: 1- [p-(2-(2-furancarboxamido)- ethyl) phenylsulfonyl] 2-imino-3-cyclohexyl-imidazolidine which, recrystallised from ethyl acetate, melts at 143-144";
(b) From 40.9 g. of l-[p-(Z-aminoethyl)-phenylsulfonyl] 2-imino-3-cyclopentyl-imidazolidine dihydrochloride (decomposition point 270) and 16.5 g. of thiophene-Z- carboxylic acid chloride is obtained: 1-[p-(2-(2-thiophenecarboxamido) ethyl) phenylsulfonyl]-2-imino-3-cyclopentyl-imidazolidine which, recrystallised from ethvl acedate/methanol melts at 169-170";
(c) From 42.3 g. of 1-[p-(Z-aminoethyl)-phenylsulfonyl] Z-imino-3-cyclohexyl-imidazolidine dihydrochloride, M.P. 147-250", and 16.5 g. of thiophene-Z-carboxylic acid chloride is obtained: l-[p-(2-(2-thiophenecarboxamido) ethyl) phenylsulfonyl]-2-imino-3-cyclohexyl-imidazolidine which, recrystallised from ethyl acetate, melts at 170-172;
(d) From 38.3 g. of 1-[p-(2-aminoethyl)-phenylsulfonyl] 2 imino-3-propyl-imidazo1idine dihydrochloride, M.P. 255-256", and 16.0 g. of nicotinic acid chloride is obtained: 1 [p-Z-nicotintmidoethyl)-phenylsulfonyl]-2- imino-3-propyl-imidazolidine which, recrystallised from ethyl acetate/methanol, melts at 163-164;
(c) From 38.3 g. of 1-[p-(2-aminoethyl)-phenylsul fonyl] 2 imino-3-isopropyl-imidazolidine dihydrochloride, M.P. 249-250, and 16.0 g. of nicotinic acid chloride is obtained: l- [p-(2-nicotinamidoethyl-phenylsulfonyl]-2-imino-3-isopropyl-imidazolidine which, recrystallised from ethyl acetate/methanol, melts at 201202;
(f) From 39.7 g. of 1-[p-(Z-aminoethyl)-phenylsulfonyl 2 imino-3-isobutyl-imidazolidine dihydrochloride, M.P. 249-250, and 16.0 g. of nicotinic acid chloride is obtained: 1 [p (2-nicotinamidoethyl)-phenylsulfonyl]- 2-imino-3 isobutyl imidazolidine which, recrystallised from ethyl acetate, melts at 154-l56;
(g) From 39.7 g. of 1-[p-2-aminoethyl)-phenylsulfonyl] 2 imino-3-tert.butyl-imidazolidine dihydrochloride, M.P. 232-234", and 16.0 g. of nicotinic acid chloride is obtained: 1-[p-2-nicotinamidoethyl)-phenylsufonyl]-2- imino-3-tert.butyl-imidazolidine which, recrystallised from ethyl acetate, melts at 191-194";
(h) From 42.3 g. of 1-[p-(Z-aminoethyl)-phenylsulfonyl] 2 imino-3-cyclohexyl-imidazolidine dihydrochloride, M.P. 247-250, and 16.0 g. of nicotinic acid chloride is obtained: 1-[p-(Z-nicotinamidoethyl)-phenylsulfonyl] 2 imino-3-cyclohexyl-imidazolidine which, recrystallised from ethyl acetate, melts at 170-171";
(i) From 39.7 g. of 1-[p-(Z-aminoethyl)-phenylsulfonyl] 2 imino-3-butyl-imidazolidine dihydrochloride, M.P. 259-260, and 16.0 g. of isonicotinic acid chloride is obtained 1 [p (2-isonicotinamidoethyl)-phenylsulfonyl]-2-imino-3-butyl-imidazolidine which, recrystallised from ethyl acetate/methanol, melts at 163-165;
(j) From 39.7 g. of 1-[p-2-aminoethyl)-phenylsulfonyl] 2 imino-3-tert.butyl-imidazolidine dihydrochloride, M.P. 232-234", and 16.0 g. of isonicotinic acid chloride is obtained: 1 [p-(Z isonicotinamidoethyl)- phenylsulfonyl]-2-imino-3-tert.butyl-imidazolidine which,
recrystallised from ethyl acetate/ methanol, melts at 170.5- 171.5;
(k) From 39.7 g. of 1-[p(2-aminoethyl)-phenylsulfonyl] 2 imino-3-butyl-imidazolidine dihydrochloride, M.P. 259-260, and 20.5 g. of 4-phenyl-3-isoxazole'carboxylic acid chloride is obtained: 1-[p-(2-(4-phenyl-3- isoxazolecarboxamido) ethyl)-phenylsulfonyl]-2-imino- 3butyl-imrnidazoline which, recrystallised from ethyl acetate/methylene chloride, melts at 129-130.
The dihydrochlorides (used as starting materials) of 1 [p (2 aminoethyl) phenylsulphonyl]-2-iminoimidazolidines varying substituted in the 3-position can be obtained, e.g. in a simple manner by reaction of p-(2- acylamidoethyl)-benzenesulphochloride with correspondingly substituted 2amino-imidazolines of Formula V, and subsequent hydrolytic cleavage of the acyl radical of the p-acylamindoethyl group with aqueous hydrochloric acid, as is described in the following for 1-[p-(2-aminoethyl)- phenylsulphonyl] 2 imino-3-cyclohexyl-imidazolidine dihydrochloride.
(a) An amount of 40.8 g. of l-cyclohexyl-Z-aminoimidazoline hydrochloride is added to a solution of 17 g. of sodium hydroxide in 170 ml. of Water. The obtained clear solution is mixed with a solution of 52.4 g. of p-(2- acetamidoethyl)-benzenesulphochloride in 200 ml. of acetone, whereby heating occurs. The mixture is heated for half an hour to and then concentrated in vacuo to dryness. The thus obtained crude l-[p-(Z-acetamidoethyl)-phenylsulphonyl[-2-imino-3-cyclohexyl imidazolidine melts, after recrystallisation from ethyl acetate, at 181-183.
The applied sulphochlor-ide can be produced as follows: To 35.0 g. of chlorosulphonic acid are added portionwise, with stirring, 16.3 g. of N-phenethylacetamide. The obtained mixture is stirred for 3 hours at 60, and then poured on to ice, whereby p-(Z-acetamidoethyl)-benzenesulphochloride precipitates in crystalline form. It is filtered 01f under suction, washed with water, dried in vacuco, and further processed as crude product.
(b) A solution of 39.2 g. of the I-[p-(Z-acetamidoethyl). phenylsulphonyl]-2-imino-3-cyclohexyl-imidazolidine in 370 ml of 2-n hydrochloric acid is refluxed for 6 hours, and suhsequentliy concentrated in vacuo to dryness. The crude oily 1-[p-(Z-aminoethyl)-phenylsulphonyl] 2 imino-3-cyclohexyl-imidazolidine dihydrochloride is taken up with warm ethanol. It crystallises in the cold state from the ethanolic solution and melts at 247-250".
Example 2 42.3 g. of 1-[p-(2-aminoethyl)-phenylsulfonyl]-2- irnino-3-cyclohexyl-imidazolidine dihydrochloride, M.P. 247-25 0 are dissolved in 200 ml, of Zn sodium hydroxide the free base is extracted with methylene chloride, the extract is dried over sodium sulfate and the methylene chloride is distilled off in vacuo. The residue is then taken up with 300 ml. of dioxane and after addition of 16.0 g. of nicotinic acid methyl ester and 0.5 g. of sodium methylate the whole is refluxed for 4 hours. The solvent is distilled oil? in vacuo and the residue is taken up with hot acetic acid ethyl ester and the obtained solution is filtered while hot. After cooling to room temperature the 1- [p-(2-nicotinamidoethyl) phenylsulfonyl] 2 imino-3-cyclohexylimidazolidine precipitates, M.P. 170-171".
Example 3 42.3 g. of 1-[p-(Z-aminoethyl)-phenylsulphonyl]-2- imino-3-cyclohexyl-imidazolidine dihydrochloride, M.P. 247-25 0 are dissolved in 200 ml. of water. After addition of ml. of 2-n sodium hydroxide the free base is taken up with methylenechloride and the methylenechloride solution is dried over sodium sulphate. Then 12.3 g. of nicotinic acid and 60 g. of N,N'-dicyclohexy1 carbodiimide are added. The whole is kept for 1 hour at room temperature and evaporated to dryness in vacuo. The residue is shaken with a mixture of ethyl acetate and 2-n hydrochloric acid. Then the whole is filtered to remove the N,N-dicyclohexyl urea. The acid aqueous phase is separated. While cooling with ice concentrated sodium hydroxide solution is added and the free base is taken up with methylene chloride. The extract is dried over sodium sulphate and the solvent is distilled off in vacuo and the crude 1 [p (2-nicotinamidoethyl)-phenylsulphonyl]-2- imino-3-cyclohexyl-imidazolidine obtained is recrystallised from ethyl acetate, M.P. 170-171.
Example 4 Analogously to Example 1 are obtained:
From 43.7 g. 1-[p-(Z-amino-ethyl)phenylsulphonyl]-2- imino-3-cyclopentyl-4-ethyl-imidazolidine-dichloride and 17.0 g. thiophene-Z-carboxylic acid chloride, l-[p-(2-thiophenecarboxamido)-ethyl) phenylsulphonyl] 2 imino- 3-cyclopentyl-4-ethyl-imidazolidine, M.P. 144-145 From 43.7 g. 1-[p-(Z-amino-ethyl)-phenylsulphonyl]-2- imino 3 cyclohexyl 4 methyl-imidazolidine-dihydrochloride and 16.0 g. nicotinic acid chloride, 1-[p-(2-nicotinamido-ethyl)-phenylsulphonyl] 2 imino 3 cyclohexy1-4-methyl-imidazolidine;
From 43.1 g. 1-[p-(2-arnino-ethyl)-phenylsulphonyl]- 2-imino-3-benzyl-imidazolidine-dihydrochloride and 16.0 .1
g. nicotinic acid chloride, 1-[p-(Z-nicotinamido-ethyl)- phenylsulphonyH-Z-imino 3 benzyl-imidazolidine, M.P. 173-175 From 44.5 g. l-[p-(Z-amino-ethyl)-phenylsulphonyl]- 2-imino 3 (2-phenethyl)-imidazolidine-dihydrochloride and 15.0 g. furan-2-carboxylic acid chloride, 1[p-(2-(2- furancarboxamido)-ethyl)-phenylsulphonyl] 2 imino 3-(Z-phenethyl)-imidazolidine, M.P. 182-183";
From 42.5 g. 1-[p-(Z-arnino-ethyl)-phenylsulphonyl] 2-imino 3 (1,2-dimethyl-butyl)-imidazolidine-dihydrochloride and 18.0 g. S-methyl-thiophene-Z-carboxylic acid chloride, 1-[p-(2-(5-methyl 2 thiophenecarboxamido)- ethyl)-phenylsulphonyl]-2-imiuo-3-(l,2 dimethyl-butyl)- imidazolidine;
From 43.7 g. 1-[p-(Z-amino-ethyl)-phenylsulphonyl]- 2-imino 3 cycloheptyl-imidazolidine-dihydrochloride and 18.0 g. S-methylthiophene-Z-carboxylic acid chloride, 1-(p-(2-(5 methyl 2 thiophenecarboxamido)ethyl)- phenylsulphonyl]-2-imino-3-cycloheptyl-imidazolidine;
From 38.1 g. 1-[p-(Z-amino-ethyl)-phenylsulphonyl]- Z-imino 3 allyl-imidazolidine-dihydrochloride and 15.0 g. furan-Z-carboxylic acid chloride, l-[p-(2-(2-furancarboxamido)-ethyl)-phenylsulphonyl] 2 imino-3-allylimidazolidine, M.P. 134-135 From 35.5 g. 1-[p-(Z-amino-ethyl)-phenylsulphonyl-2- imino 3 methyl-imidazolidine-dichloride and 15.0 g. furan-Z-carboxylic acid chloride, I-[p-(Z-(Z-furancarboxamido)-ethyl)-phenylsulphonyl] 2 imino 3 methylimidazolidine, M.P. 210.5-211.5;
From 42.3 g. 1-[p-(Z-amino-ethyl)-phenylsulphonyl]- 2-imino 3 cyclohexyl-imidazolidine-dihydrochloride and 17.0 g. 4-methylthiazole-5-carboxylic acid chloride, 1-[p- (2-(4 methyl 5 thiazolecarboxamido)-ethyl)-phenylsulphonyl] 2 imino 3 cyclohexylirnidazolidine-monohydrate, M.P. 164-165";
From 42.3 g. 1-[p-(Z-amino-ethyl)-phenylsulphonyl]- 2 imino 3 cyclohexyl-imidazolidine-dihydrochloride and 17.0 g. 5-oxo-2-pyrrolidinecarboxylic acid chloride, 1-[-(2 (5 oxo 2 pyrrolidine-carboxamido)-ethyl) phenylsulphonyl1-2-imino 3 cyclohexyl-imidazolidine, M.P. 165;
From 42.3 g. l-[p-(Z-amino-ethyl)phenylsulphonyl]- Z-imino 3-cyclohexyl-imidazolidine-dihydrochloride and 16.0 g. picolinic acid chloride, 1-[p-(2-picolinamidoethyD-phenylsulphonyl] 2 imino 3 cyclohexyl-imidazolidine, M.P. 167-168".
From 43.7 g. 1-[p-(2-amino-ethyl)-phenylsulphonyl]- 2-imino-3-cyclopentyl 4 ethyl imidazolidine dihydrochloride and 15.0 g. furan-Z-carboxylic acid chloride,
l-[p (2 (2 furancarboxamido)-ethyl)-phenylsulphonyl]- 2-imino-3-cyclopentyl 4 ethyl-imidazolidine, M.P. 106";
From 43.7 g. 1-[p-amino-ethyl)-phenylsulphonyl]-2- imino-3-cyclohexyl 4 methyl-irnidazolidine-dihydrochloride and 15.0 g. furan-Z-carboxylic acid chloride, 1-[p-(2- (Z-furancarboxamido -ethyl -phenylsulphonyl] Z-imino- 3-cyclohexyl-4-methyl-imidazolidine, M.P. 136137; and
From 45.1 g. l-[p-(Z-amino-ethyl)-phenylsulphonyl]- 2imino-3-cyclohexyl 4 ethyl-irnidazolidine-dihydrochloride and 18.0 g. thiophene-Z-carboxylic acid chloride, 1-[p-(2 (2 thiophenecarboxamido)-ethyl)-phenylsulphonyl]-2-imino-3-cyclohexyl-4-ethyl-imidazolidine, M.P. 144-145 What is claimed is:
1. A compound of the formula wherein R is alkyl of at most six carbon atoms, cycloalkyl or alkyl substituted cycloalkyl of, in all, from five to eight carbon atoms, phenylalkyl of at most three carbon atoms in the alkyl chain, or allyl;
R is hydrogen, methyl or ethyl;
R is a five to six membered mononuclear heterocycle with one or two heteroatoms, which is unsubstituted or substituted by lower alkyl or phenyl and of which a methylene group can be replaced by a carbonyl group furan, thiophene or pyridine, which is unsubstituted or substituted by lower alkyl;
m is the integer 2 or 3;
or the pharmaceutically acceptable acid addition salts thereof.
2. A compound according to claim 1, which is 1-[p-(2- (3-furancarboxamido)-ethyl)-phenylsulfonyl] 2 imino- 3-cyclohexyl-imidazolidine.
3. A compound according to claim 1, which is 1-[p-(2- (2 thiophenecarboxamido) ethyl) phenylsulfony1]-2- imino-3-cyclopentyl-imidazolidine.
4. A compound according to claim 1, which is 1-[p-(2- (2 thiophenecarboxamido) ethyl) phenylsulfonyl]- 2-imino-3-cyclohexyl-imidazolidine.
5. A compound according to claim 1, which is 1-[p-(2- nicotinamidoethyl)-phenylsulfonyl] 2 imino 3 cyclohexyl-imidazolidine.
6. A compound according to claim 1, wherein R is furan, which is unsubstituted or substituted by lower alkyl.
References Cited UNITED STATES PATENTS 3,538,085 11/1970 Dietrich 260-309.7
OTHER REFERENCES Boehringer et al.: Chem. Abst., vol. 69, No. 36157v Dietrich et al.: Chem. Abst., vol. 72, No. 12725q (1970).
Farbwerke Hoechst: Chem. Abst., v01. 65, columns 5442-3 (1966).
Natito, Shunichi: Chem. Abst., vol. 72, No. 100696m (1970).
NATALIE TROUSOF, Primary Examiner U.S. Cl. X.R.
260-250 R, 250 A, 256.5 R, 306.7, 306.8 R, 307 R, 307 A, 307 H, 309.7, 543 R, 545 R, 556 AR; 424250, 251, 263, 266, 270, 272, 273
US00068794A 1969-09-04 1970-09-01 P-aminoalkylbenzenesulfonamide derivatives Expired - Lifetime US3712899A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH1339969A CH518944A (en) 1969-09-04 1969-09-04 Process for the preparation of new derivatives of p-aminoalkyl-benzenesulfonamide

Publications (1)

Publication Number Publication Date
US3712899A true US3712899A (en) 1973-01-23

Family

ID=4392084

Family Applications (2)

Application Number Title Priority Date Filing Date
US00068794A Expired - Lifetime US3712899A (en) 1969-09-04 1970-09-01 P-aminoalkylbenzenesulfonamide derivatives
US00290041A Expired - Lifetime US3787574A (en) 1969-09-04 1972-09-18 P-aminoalkylbenzenesulfonamide derivatives for treating diabetes mellitus

Family Applications After (1)

Application Number Title Priority Date Filing Date
US00290041A Expired - Lifetime US3787574A (en) 1969-09-04 1972-09-18 P-aminoalkylbenzenesulfonamide derivatives for treating diabetes mellitus

Country Status (19)

Country Link
US (2) US3712899A (en)
AT (1) AT294823B (en)
BE (1) BE755684A (en)
BG (1) BG18604A3 (en)
CH (1) CH518944A (en)
DE (1) DE2043809C3 (en)
DK (1) DK123939B (en)
ES (1) ES383343A1 (en)
FI (1) FI52464C (en)
FR (1) FR2070670B1 (en)
GB (1) GB1306560A (en)
IE (1) IE34503B1 (en)
IL (1) IL35223A (en)
NL (1) NL165738C (en)
NO (1) NO129741B (en)
PL (1) PL73404B1 (en)
SE (1) SE367628B (en)
SU (1) SU373944A3 (en)
ZA (1) ZA706037B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH505829A (en) * 1968-03-14 1971-04-15 Ciba Geigy Ag Process for the preparation of new derivatives of p-aminoalkylbenzenesulfonamide

Also Published As

Publication number Publication date
FI52464B (en) 1977-05-31
FI52464C (en) 1977-09-12
SE367628B (en) 1974-06-04
FR2070670A1 (en) 1971-09-17
CH518944A (en) 1972-02-15
AT294823B (en) 1971-12-10
FR2070670B1 (en) 1973-12-21
IL35223A0 (en) 1970-11-30
IL35223A (en) 1973-10-25
DE2043809B2 (en) 1979-03-22
BE755684A (en) 1971-03-03
DE2043809A1 (en) 1971-04-01
ES383343A1 (en) 1973-01-01
PL73404B1 (en) 1974-08-30
NO129741B (en) 1974-05-20
SU373944A3 (en) 1973-03-12
GB1306560A (en) 1973-02-14
NL7012726A (en) 1971-03-08
IE34503B1 (en) 1975-05-28
NL165738C (en) 1981-05-15
US3787574A (en) 1974-01-22
IE34503L (en) 1971-03-04
NL165738B (en) 1980-12-15
BG18604A3 (en) 1975-02-25
DE2043809C3 (en) 1979-11-15
DK123939B (en) 1972-08-21
ZA706037B (en) 1971-04-28

Similar Documents

Publication Publication Date Title
EP1203767B1 (en) Heterocyclic-substituted alkylamide acat inhibitors
US3505350A (en) Certain substituted 2-mercaptoimidazole derivatives
US3818014A (en) 2-quinolyl-4(5)-trifluoromethylimidazoles
US4954498A (en) Tricyclic benzimidazole compounds, pharmaceutical compositions and methods of use
US3459763A (en) Certain amino imidazole derivatives
FI70708C (en) PHARMACEUTICAL FORM OF THE PHARMACEUTICAL FORM OF THE PHARMACEUTICAL FORM OF 2-IMIDAZOLIN-1-YL-URINAEMNE- OCH -AMIDOFOERENINGAR
US3712899A (en) P-aminoalkylbenzenesulfonamide derivatives
US5380723A (en) Indole derivatives
EP0632040A1 (en) Antibacterial imidazole derivatives
US3708493A (en) P-(acetoacetamidoalkyl)benzenesulfonamide derivatives
US3829434A (en) Piperidinesulfonylurea derivatives
US3705151A (en) Benzene-sulfonyl semicarbazides and process for preparing them
US4847251A (en) Pyridazinone derivatives, and pharmaceutical compositions containing them
US3975524A (en) 3-Piperazino-isoquinolines and salts thereof
US3812144A (en) Derivatives of p-aminoalkylbenzene sulfonamide
US4247705A (en) 4-Substituted 2-iminoimidazolidine compounds
US3941804A (en) 1-Heteroarylsulphonyl-2-imino-imidazolidines
US3729462A (en) P-aminoalkylbenzenesulfonamide derivatives
US3708494A (en) Derivatives of p-aminoalkylphenylsulfonyl-2-imino-imidazolidines
US3712905A (en) P-carbamoylethylphenylsulfonyl derivatives
US4327107A (en) Method useful in the treatment of sugar cataracts using 4-substituted-2-iminoimidazolidine compounds
US3853876A (en) Ortho-mercaptoaroylamides and salts thereof abstract of the disclosure
CA1046060A (en) Substituted n-acyl-n"-(3-amino-2-cyano-acryloyl)-formamidrazones
US3502684A (en) N-(2-(2-aza-adamant-2-yl)-ethyl)-guanidines
US4389403A (en) 1-Aroyl-2-phenylamino-2-imidazolines, drugs containing these compounds, and use thereof